Log In
BCIQ
Print this Print this
 

ABT-719, ZP1480 (formerly AP214)

  Manage Alerts
Collapse Summary General Information
Company Zealand Pharma A/S
DescriptionAlpha-melanocyte-stimulating hormone analog
Molecular Target Melanocortin 1 receptor (MC1R) ; Melanocortin 3 receptor (MC3R)
Mechanism of ActionMelanocortin 1 receptor (MC1R) agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationRenal damage
Indication DetailsPrevent acute kidney injury (AKI) following major cardiac surgery; Treat acute kidney injury (AKI)
Regulatory Designation
PartnerAbbVie Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$110.0M

$110.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/07/2012

$110.0M

$110.0M

0

Get a free BioCentury trial today